These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21638324)

  • 1. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
    Gallagher CL; Christian BT; Holden JE; Dejesus OT; Nickles RJ; Buyan-Dent L; Bendlin BB; Harding SJ; Stone CK; Mueller B; Johnson SC
    Mov Disord; 2011 Sep; 26(11):2032-8. PubMed ID: 21638324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
    Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
    Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of 6-[
    Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
    J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.
    Asari S; Fujimoto K; Miyauchi A; Sato T; Nakano I; Muramatsu S
    BMC Neurol; 2011 Mar; 11():35. PubMed ID: 21429212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
    Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
    Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
    Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
    J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
    Nahmias C; Wahl L; Chirakal R; Firnau G; Garnett ES
    Mov Disord; 1995 May; 10(3):298-304. PubMed ID: 7651447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
    Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):314-9. PubMed ID: 9527140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
    Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
    Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
    J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
    Wahl L; Nahmias C
    J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P; Gjedde A
    Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
    Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ
    Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
    Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
    J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
    Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
    Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.